CNS Pharmaceuticals
CNSP
11 hedge funds and large institutions have $422K invested in CNS Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.
664% more capital invested
Capital invested by funds: $55.2K → $422K (+$367K)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
57% more funds holding
Funds holding: 7 → 11 (+4)
0.67% more ownership
Funds ownership: 0.12% → 0.78% (+0.67%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$423K |
| 2 |
VF
Virtu Financial
New York
|
+$24.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$16.3K |
| 5 |
HF
HRT Financial
New York
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$15.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $335K | +$423K | +33,833 | New |
|
2
UBS Group
Zurich,
Switzerland
| $26.5K | +$8.47K | +677 | +34% |
|
|
VF
3
Virtu Financial
New York
| $19K | +$24.4K | +1,946 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $14.7K | +$18.6K | +1,489 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $12.9K | +$16.3K | +1,303 | New |
|
|
HF
6
HRT Financial
New York
| $8K | +$11.3K | +905 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $5.56K | +$1.7K | +136 | +32% |
|
|
BC
8
Barrett & Company
Providence,
Rhode Island
| $83 | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $40 | +$38 | +3 | +300% |
|
|
MCM
10
MAI Capital Management
Independence,
Ohio
| $33 | – | – | – |
|
|
SS
11
SBI Securities
Tokyo,
Japan
| $11 | – | – | – |
|
|
GSC
12
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$15.4K | -945 | Closed |
|
CNSP Hedge Fund Activity: Q2 2025 in Review
11 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q2 2025, worth a combined $422K — up 664% from $55.2K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CNSP positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $423K. The largest seller was Ground Swell Capital, exiting entirely with an estimated $15.4K sold.
- 11 institutional investors held CNS Pharmaceuticals (CNSP) as of Q2 2025, up from 7 in Q1 2025.
- Funds reported $422K of CNS Pharmaceuticals stock for Q2 2025, up 664% quarter-over-quarter.
- 5 funds opened new CNS Pharmaceuticals positions in Q2 2025 and 1 closed out, a net change of +4 holders.
- The largest CNS Pharmaceuticals buyer in Q2 2025 was Armistice Capital, an estimated $423K added.
- The largest CNS Pharmaceuticals seller in Q2 2025 was Ground Swell Capital, an estimated $15.4K sold.
Based on aggregated 13F filings for Q2 2025.